Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Parasitol Res ; 118(6): 1741-1749, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31049694

ABSTRACT

Monogeneans are a diverse group of parasites that are commonly found on fish. Some monogenean species are highly pathogenic to cultured fish. The present study aimed to determine the in vitro anthelmintic effect of silver nanoparticles (AgNPs) against adults and eggs of monogeneans in freshwater using Cichlidogyrus spp. as a model organism. We tested two types of AgNPs with different synthesis methodologies and size diameters: ARGOVIT (35 nm) and UTSA (1-3 nm) nanoparticles. Damage to the parasite tegument was observed by scanning electron microscopy. UTSA AgNPs were more effective than ARGOVIT; in both cases, there was a concentration-dependent effect. A concentration of 36 µg/L UTSA AgNPs for 1 h was 100% effective against eggs and adult parasites, causing swelling, loss of corrugations, and disruption of the parasite's tegument. This is an interesting result considering that monogenean eggs are typically tolerant to antiparasite drugs and chemical agents. To the best of our knowledge, no previous reports have assessed the effect of AgNPs on any metazoan parasites of fish. Therefore, the present work provides a basis for future research on the control of fish parasite diseases.


Subject(s)
Antiplatyhelmintic Agents/pharmacology , Eggs/parasitology , Fish Diseases/parasitology , Metal Nanoparticles/toxicity , Silver/pharmacology , Trematoda/drug effects , Trematode Infections/veterinary , Animals , Anthelmintics , Antiplatyhelmintic Agents/chemistry , Female , Fish Diseases/drug therapy , Fishes , Male , Metal Nanoparticles/chemistry , Silver/chemistry , Trematoda/physiology , Trematode Infections/drug therapy , Trematode Infections/parasitology
2.
Gac Med Mex ; 151(2): 245-51, 2015.
Article in Spanish | MEDLINE | ID: mdl-25946535

ABSTRACT

Alzheimer's disease is the most common cause of dementia in the world; symptoms first appear after age 65 and have a progressive evolution. Expecting an increase on its incidence and knowing there is currently no cure for Alzheimer's disease, it is a necessity to prevent progression. The change in diet due to globalization may explain the growth of the incidence in places such as Japan and Mediterranean countries, which used to have fewer incidences. There is a direct correlation between disease progression and the increased intake of alcohol, saturated fats, and red meat. Therefore, we find obesity and higher serum levels in cholesterol due to saturated fat as a result. A way to decrease the progression of Alzheimer's is through a diet rich in polipheno/es (potent antioxidants), unsaturated fats (monounsaturated and polyunsaturated), fish, vegetable fa t, fruits with low glycemic index, and a moderate consumption of red wine. Through this potent antioxidant diet we accomplish the prevention of dementia and the progression of Alzheimer's disease. This article emphasizes the food and other components that have been demonstrated to decrease the oxidative stress related to these progressive diseases.


Subject(s)
Alzheimer Disease/etiology , Alzheimer Disease/prevention & control , Diet , Oxidative Stress , Humans
3.
Virus Genes ; 29(2): 257-65, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15284486

ABSTRACT

We report a fast, highly sensitive method for detecting and testing drug resistance of M-tropic and T-tropic laboratory and primary HIV-1 isolates. cMAGI cells are infected with an adenovirus vector harboring the luciferase reporter gene controlled by HIV-1 Tat-responsive element, TAR. HIV-1 Tat production by HIV-1 chronically infected cells, or by cMAGI cells as early as two days after being acutely infected with HIV-1, is readily monitored in the presence or absence of antiviral drugs. This method is more sensitive than HIV-1 Tat dependant production of beta-galactosidase in the cMAGI cells. The fast answer, ease and sensitivity as well as the possibility of using this method in high throughput screening, makes it an very attractive tool for phenotypic detection of HIV-1 in clinical samples as well as a sensitive assay for monitoring drug resistant HIV-1 variants. This method can also be used for discovery of novel anti HIV-1 drugs.


Subject(s)
Anti-HIV Agents/pharmacology , CD4-Positive T-Lymphocytes/virology , Genes, Reporter , HIV-1/drug effects , Luciferases/metabolism , Luminescent Proteins/metabolism , Adenoviridae/genetics , Adenoviridae/metabolism , Adenoviridae/pathogenicity , Cell Line , Gene Expression Regulation , Gene Products, tat/metabolism , Genetic Vectors , HIV Long Terminal Repeat , HIV-1/pathogenicity , Humans , Luciferases/genetics , Luminescent Proteins/genetics , Microbial Sensitivity Tests/methods , Sensitivity and Specificity , Time Factors , tat Gene Products, Human Immunodeficiency Virus
4.
Biochem Biophys Res Commun ; 312(4): 1047-52, 2003 Dec 26.
Article in English | MEDLINE | ID: mdl-14651977

ABSTRACT

Aminoglycoside-arginine conjugates (AACs) inhibit HIV-1 replication and act as Tat antagonists. AACs compete with monoclonal antibody binding to CXCR4, compete with SDF-1alpha and HIV-1 gp120 cellular uptake, indicating that they interfere with initial steps of HIV-1 infection. We here present the selection of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate (NeoR6), the most potent anti-HIV-1 AAC. We found in the NeoR6-resistant isolates the following mutations in gp120: I339T in the C3 region, S372L in the V4 region, and Q395K in the C4 region; and in gp41: S668R and F672Y in the 'heptad repeat' 2 (HR2) region. These findings strongly suggest that NeoR6 obstructs HIV-1 replication by interfering with the fusion step, dependent on both conformational changes in gp120 following CD4 and CXCR4 interaction, as well as by conformational changes in gp41 induced by HR1 and HR2 interaction. The AACs may thus represent a novel family of fusion inhibitors.


Subject(s)
Drug Resistance/physiology , Framycetin/analogs & derivatives , Framycetin/pharmacology , HIV Envelope Protein gp120/metabolism , HIV Envelope Protein gp41/metabolism , HIV-1/drug effects , HIV-1/growth & development , Drug Resistance/drug effects , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp41/genetics , HIV-1/isolation & purification , Humans , Mutagenesis, Site-Directed , Mutation , Structure-Activity Relationship
5.
Antiviral Res ; 60(3): 181-92, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14638394

ABSTRACT

We have recently designed and synthesized aminoglycoside-arginine conjugates (AACs) as potential anti-HIV-1 agents. AACs exert a number of activities related to Tat antagonism. We here present a new set of AACs, conjugates of neomycin B, paromomycin, and neamine with different number of arginines (1-6), their (a) uptake by human T-cell lines, (b) antiviral activities, (c) competition with monoclonal antibody (mAb) 12G5 binding to CXCR4, (d) competition with stromal cell-derived factor-1 (SDF-1alpha) binding to CXCR4, and (e) competition with HIV-1 coat protein gp120 cell penetration. The appearance of mutations in HIV-1 gp120 gene in AACs resistant HIV-1 isolates, supports that AACs inhibit HIV-1 infectivity via interference of gp120-CXCR4 interaction. Our results point that the most potent AACs is the hexa-arginine-neomycin conjugate, the other multi-arginine-aminoglycoside conjugates are less active, and the mono-arginine conjugates display the lowest activity. Our studies demonstrate that, in addition to the core, the number of arginines attached to a specific aminoglycoside, are also important in the design of potent anti-HIV agents. The AACs play an important role, not only as HIV-1 RNA binders but also as inhibitors of viral entry into human cells.


Subject(s)
Anti-HIV Agents/pharmacology , Arginine , Framycetin/analogs & derivatives , HIV Envelope Protein gp120/metabolism , HIV-1/drug effects , Neomycin/chemistry , Neomycin/pharmacology , Receptors, CXCR4/metabolism , Anti-HIV Agents/chemistry , Anti-HIV Agents/metabolism , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Cell Line , Cells, Cultured , Chemokine CCL5/pharmacology , Chemokine CXCL12 , Chemokines, CXC/pharmacology , Drug Resistance, Viral/genetics , Framycetin/chemistry , Framycetin/metabolism , Framycetin/pharmacology , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp120/pharmacology , HIV-1/genetics , HIV-1/growth & development , HIV-1/metabolism , Humans , Leukocytes, Mononuclear/metabolism , Neomycin/metabolism , Paromomycin/chemistry , Paromomycin/metabolism , Paromomycin/pharmacology , Receptors, CXCR4/immunology , Structure-Activity Relationship , Virus Replication/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...